Drug Trial Radar · NCT06810245
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Feb 4, 2025
Primary completion
Jan 20, 2026
Study completion Jan 20, 2026
Sponsor
- Lead sponsor
- Contineum TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.
Conditions
- Chronic Osteoarthritis Pain
- Chronic Low Back Pain
Interventions
PIPE-791Drug
PIPE-791 tablet, taken once daily for 4 weeks
PlaceboDrug
Placebo tablet, taken once daily for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with Treatment-emergent adverse events (TEAEs)Time frame: For Treatment Period 1, from Baseline (Day 1) to End of Treatment Period 1 (TP1; Day 29), for Treatment Period 2, from Baseline of Treatment Period 2 (TP2; Day 29) to End of TP2 (Day 57).
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Arizona Research Center
Phoenix, Arizona
Drug Studies America
Marietta, Georgia
Drug Trials America
Hartsdale, New York
Altoona Center of Clinical Research
Duncansville, Pennsylvania
JBR Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.